9 May 2017

Sareum Holdings PLC

(“Sareum” or the “Company”)

Sareum to Present at BioTrinity 2017

Dr Tim Mitchell, CEO of Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development business, will be giving two presentations at BioTrinity 2017 currently being held at the Novotel London West, Hammersmith International Centre, London until 10th May.

Dr Mitchell will be showcasing the Company and its lead programmes in the “Early Stage Therapeutics 1” session today at 13.50pm and has been invited by the organisers to present to a panel of investors tomorrow (10th May) at the “Perfect Pitch” session being held at 15:00.

BioTrinity is one of Europe's leading biopartnering and investment conferences, and the largest of its type in the UK. The event is attended by global life science investors, big pharma executives and emerging R&D companies. 

Dr Tim Mitchell, CEO of Sareum, commented: “BioTrinity offers us ideal opportunities to present our latest developments to both investors and potential licence partners.”

John Harris, CEO of OBN, said: “We are delighted that Sareum will be presenting at BioTrinity this year. BioTrinity is the perfect platform for life science companies to showcase their innovation and seek out their next deal. This year again we are thrilled to be hosting what we believe will be the great business development opportunity of 2017.”

For further information, please contact:

Sareum Holdings plc


Tim Mitchell

01223 497 700

WH Ireland Limited (Nominated Adviser and Co-Broker)

Chris Fielding / Nick Prowting

020 7220 1666

Hybridan LLP (Co-Broker)


Claire Noyce

020 3764 2341

The Communications Portfolio (Sareum Media enquiries)


Ariane Comstive

07785 922 354

Notes for editors:

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and licensing them to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum operates an outsourced research model, working with international collaborators and a world-wide network of research providers. Its most advanced programme (Chk1) commenced clinical trials in May 2016 and was licensed to NASDAQ-listed Sierra Oncology in September 2016.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease research programmes, which are in the IND-enabling preclinical and lead optimisation stages respectively. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk

About BioTrinity

Founded and produced by OBN, BioTrinity is now in its 11th year. BioTrinity continues to grow with more than 1000 senior executives and decision makers from emerging and established companies across the life sciences sector and investment firms are expected to attend.

About OBN

OBN is the Membership organisation supporting and bringing together the UK’s innovative life sciences companies, corporate partners and investors. Our 400-plus member companies are located across the Golden Triangle and beyond to Nottingham, Manchester and Scotland and benefit from our networking, partnering, purchasing, advising and advocacy activities.  OBN is best known for its delivery of BioTrinity (11th edition: May 9-10, 2017), Europe’s leading life sciences investment and biopartnering conference, visit www.biotrinity.com for more information.

Further information about OBN’s tailored networking and partnering events, purchasing consortium, advice, consultancy services and advocacy activities is available on OBN’s website www.obn.org.uk .


OBN: Jane O’Driscoll, Head of Events, Tel: +(44) 1235 420 875, Email: Jane.odriscoll.co.uk

Citigate Dewe Rogerson Sylvie Berrebi Tel: +44(0)20-7638-9571 Email:  Sylvie.berrebi @citigatedr.co.uk